FDA Grants Fast Track Designation to EpicentRx’s RRx-001 for Severe Oral Mucositis Prevention in Head & Neck Cancer Patients
EpicentRx, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001, a novel compound with direct NLRP3 inhibitory and Nrf2 upregulatory effect ...
USA: PD 1 Utilization in Advance and Metastatic Squamous Cell Carcinoma of the Head and Neck – 2022
[vc_row][vc_column][vc_custom_heading text="USA: PD 1 Utilization in Advance and Metastatic Squamous Cell Carcinoma of the Head and Neck - 2022" font_container="tag:h2|text_align:center" use_theme_fon ...